drugset
drugset / Trial / NCT02777671

Effect of Eslicarbazepine Acetate on the Pharmacokinetics of Gliclazide in Healthy Volunteers

NCT02777671 ↗

Phase 1 Completed 20 enrolled Bial - Portela C S.A.
RandomizedCrossoverOpen-labelTreatment

Summary

Single centre, randomised, open-label, two-way crossover study to investigate whether multiple-dose administration of eslicarbazepine acetate (ESL, BIA 2-093) affects the pharmacokinetics of gliclazide.

Timeline

Start
2007-10
Primary completion
2007-12
Completion
2007-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown — —
Subject Gliclazide Small molecule 80 mg —

Indications

epilepsy